Clinical trials: HIV Seronegativity
HIV Infections
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men.
- Trial name
- NCT00865566
- Testing
- DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine
- Where
- 22 sites in United States
- Volunteers
- 2,504 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots
This study will assess the distribution of a microbicidal gel in the vagina and confirm the presence of bare spots. MRIs will be done with and without the addition of the MRI contrast Gadolinium to the microbicide in order to…
- Trial name
- NCT00214812
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Biosyn
HIV Infections, Syphilis
Estimating the Incidence of HIV Infection Among Men Who Have Sex With Men in Peru and Ecuador
The purpose of this observational study is to estimate the number of new HIV infections and the number and variability of antiretroviral-resistant HIV strains among men who have sex with men (MSM).
- Conditions
- HIV Infections, Syphilis, Sexually Transmitted Diseases
- Trial name
- NCT00279331
- Where
- 6 sites in Ecuador, Peru
- Volunteers
- 2,608 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Trial of SAVVY Vaginal Gel and HIV in Nigeria
Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of…
- Trial name
- NCT00130078
- Testing
- 1.0% C31G SAVVY vaginal gel
- Where
- 2 sites in Nigeria
- Volunteers
- 2,142 people, healthy volunteers welcome
- Sponsor
- Biosyn
HIV Infections
FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
This Phase III, double-blind, randomized, placebo-controlled trial enrolled HIV-negative women from 4 sites in 3 countries (Kenya, Tanzania, South Africa).
- Trial name
- NCT00625404
- Testing
- Truvada
- Where
- 4 sites in Kenya, South Africa and 1 more
- Volunteers
- 2,120 people, healthy volunteers welcome
- Sponsor
- FHI 360
HIV Infections
A Behavioral Intervention to Reduce Sexual Risk Among African-American Men Who Have Sex With Men
The purpose of this project is to test the efficacy of an HIV prevention behavioral intervention to reduce sexual risk among African-American men who have sex with men (MSM).
- Trial name
- NCT00691496
- Testing
- Behavioral intervention to reduce sexual risk among African-American men who have sex with men
- Where
- United States
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects
To evaluate an HIV synthetic lipopeptide candidate vaccine component, P3C541b, at two dose levels, administered subcutaneously (s.c.) in a randomized, double-blind, placebo controlled study.
- Trial name
- NCT00000845
- Testing
- P3C541b Lipopeptide
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Sexually Transmitted Diseases
A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs
This study will determine the effectiveness of a peer outreach intervention in preventing HIV infection in adults at high risk for contracting HIV and other sexually transmitted diseases (STDs).
- Trial name
- NCT00183456
- Testing
- Peer-oriented intervention, Group cognitive behavioral therapy (CBT)
- Where
- United States
- Volunteers
- 746 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections, HIV Seronegativity
Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
The purpose of this study is to see if the experimental vaccine, ALVAC-HIV (vCP1452) is safe and to study how the immune system responds to the vaccine.
- Trial name
- NCT00027261
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452)
- Where
- 13 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Rapid HIV Testing Program in the Emergency Department
The purpose of the study is to evaluate the feasibility of a rapid HIV testing program in the Temple University Hospital(TUH)Emergency Department.
- Trial name
- NCT00548041
- Testing
- HIV test by oral swab
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Temple University
HIV Infections
A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
To expand the available data regarding the safety and immunogenicity of 2 HIV-1 vaccine strategies: canarypox vector vCP205, or vCP205 with SF-2 rgp120.
- Trial name
- NCT00000871
- Testing
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, MN rgp120/HIV-1 and A244 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205)
- Where
- 18 sites in United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers
It is probable that a mucosal approach is necessary for a prophylactic HIV vaccine protecting against sexually transmitted infection.
- Trial name
- NCT00122564
- Testing
- HIV-1 gp 160, DC-Chol
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B
24 healthy male and female volunteers who are at low risk of HIV infection and entered into the RISVAC02 study and were randomly allocated to receive 3 intramuscular injections of MVA-B at weeks 0, 4 and 16 will receive a…
- Trial name
- NCT01923610
- Testing
- Experimental
- Where
- 2 sites in Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
HIV Infections
Male Circumcision and HIV Rates in Kenya
The Luo tribe of Kisumu, Kenya, does not traditionally practice male circumcision (MC). This study will work with the Luo tribe to test the effectiveness of MC on reducing the risk of HIV infections in young men.
- Trial name
- NCT00059371
- Testing
- male circumcision
- Where
- Kenya
- Volunteers
- 2,887 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults
The purpose of this study is to see if the experimental HIV vaccine pGA2/JS2 is safe and is well tolerated at two different doses.
- Trial name
- NCT00043511
- Testing
- pGA2/JS2 Plasmid DNA Vaccine
- Where
- 4 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Motiv82Change: an HIV Prevention Study for Young Latino Men
The purpose of this study is to develop and pilot test a culturally and developmentally tailored Motivational Enhancement Intervention (MEI) to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic…
- Trial name
- Motiv82Change (NCT00877695)
- Testing
- Entre Culturas: Navigating Culture, Identity, and HIV Risk
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nova Southeastern University
HIV Infections, HIV Seronegativity
A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
The purpose of this study is to see if it is safe to give an HIV vaccine (vCP205) to volunteers who received an HIV vaccine at least 2 years ago, and to study how the immune system responds to this vaccine.
- Trial name
- NCT00001136
- Testing
- ALVAC-HIV MN120TMG (vCP205)
- Where
- 6 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Gonorrhea
Cellulose Sulfate (CS) Gel and HIV in Nigeria
This is a Phase 3, multi-center, randomized, placebo-controlled trial to determine the effectiveness and safety of the 6% cellulose sulfate (CS) vaginal gel for the prevention of HIV infection.
- Conditions
- HIV Infections, Gonorrhea, Chlamydia Infections
- Trial name
- NCT00120770
- Testing
- Cellulose Sulfate Vaginal Gel (Microbicide)
- Where
- 2 sites in Nigeria
- Volunteers
- 2,160 people, healthy volunteers welcome
- Sponsor
- FHI 360
HIV Infections
Effectiveness of Communication Technology in Disseminating HIV Prevention Training to Non-governmental Organizations
This study will compare the effectiveness of face-to-face training versus Web-based training seminars in disseminating HIV prevention interventions to nongovernmental organizations in Eastern Europe and Central Asia.
- Trial name
- NCT00698529
- Testing
- Face-to-face training, Distance training, Popular Opinion Leader (POL)
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
HIV Infections
Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery
A new approach to HIV prevention currently being studied includes the use of topical microbicides, substances that kill microbes.
- Trial name
- NCT00540605
- Testing
- Tenofovir 1% vaginal gel
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)